Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

Key Takeaways

• 35% death‑risk reduction; median OS 16.0 vs 11.9 months
• Benefit observed regardless of recent taxane exposure or sub‑group
• FDA‑approved, NCCN‑preferred regimen for platinum‑resistant ovarian cancer
• Trial enrolled 381 patients across North America, Europe, Asia, and Latin America

Pulse Analysis

Ovarian cancer remains the fifth leading cause of cancer death among women, with platinum‑resistant disease accounting for roughly 20,000 new U.S. cases each year. Conventional chemotherapy offers modest benefit, and the tumor microenvironment often blunts drug efficacy. Recent research has highlighted cortisol’s role in suppressing apoptosis and promoting immune evasion, creating a rationale for targeting the glucocorticoid receptor (GR). Corcept’s selective GR antagonist, relacorilant, aims to reverse this resistance, positioning Lifyorli as a novel biologic approach that complements taxane‑based regimens.

The ROSELLA Phase 3 trial enrolled 381 patients across North America, Europe, Asia and Latin America, randomizing them 1:1 to receive relacorilant plus nab‑paclitaxel or nab‑paclitaxel alone. The combination achieved a 35% reduction in mortality risk (HR 0.65, p = 0.0004) and lifted median overall survival to 16.0 months versus 11.9 months for chemotherapy alone. Importantly, the survival advantage persisted in every prespecified subgroup, including those who had received a taxane within six months, underscoring the regimen’s broad applicability. Safety was comparable to the control arm, with common adverse events such as neutropenia and fatigue aligning with expectations for weekly nab‑paclitaxel.

From a commercial perspective, Lifyorli’s March 2026 FDA approval and inclusion in NCCN guidelines create a clear market entry point in a high‑unmet‑need segment. The drug’s oral administration and lack of required biomarker testing simplify adoption, while the GR‑antagonist platform opens avenues for expansion into other solid tumors where cortisol‑driven resistance is implicated. Investors will watch Corcept’s pipeline closely, as success in ovarian cancer could accelerate trials in platinum‑sensitive ovarian, endometrial, pancreatic and prostate cancers, potentially establishing a new class of adjunctive oncology therapies.